Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Commitment point during G0-->G1 that controls entry into the cell cycle.

Nicholas C Lea1, Stephen J Orr, Kai Stoeber

  • 1Department of Haematological Medicine, Leukaemia Sciences Laboratories, Guy's, King's and St. Thomas' School of Medicine, London SE5 9NU, United Kingdom.

Molecular and Cellular Biology
|March 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Expression of Concern: FOXM1 Confers Acquired Cisplatin Resistance in Breast Cancer Cells.

Molecular cancer research : MCR·2026
Same author

Expression of Concern: The p38 MAPK-MK2 Axis Regulates E2F1 and FOXM1 Expression after Epirubicin Treatment.

Molecular cancer research : MCR·2026
Same author

Retraction: Senescent Stromal Cells Promote Cancer Resistance through SIRT1 Loss-Potentiated Overproduction of Small Extracellular Vesicles.

Cancer research·2026
Same author

Expression of Concern: SIRT Inhibitors Induce Cell Death and p53 Acetylation through Targeting Both SIRT1 and SIRT2.

Molecular cancer therapeutics·2026
Same author

Expression of Concern: Gefitinib (Iressa) Represses FOXM1 Expression via FOXO3a in Breast Cancer.

Molecular cancer therapeutics·2026
Same author

Expression of Concern: The Transcription Factor FOXO3a is a Crucial Cellular Target of Gefitinib (Iressa) in Breast Cancer Cells.

Molecular cancer therapeutics·2026

Researchers identified a critical G(0) to G(1) commitment point in T-lymphocyte activation, occurring 3-5 hours post-stimulation. This point is essential for cell cycle entry and growth but not for early effector function development.

Area of Science:

  • Immunology
  • Cell Biology
  • Molecular Biology

Background:

  • T-lymphocyte activation requires cell cycle entry for proliferation and effector molecule expression.
  • A specific commitment point during the G(0) to G(1) transition that commits T cells to the cell cycle has not been previously defined.

Purpose of the Study:

  • To define the precise commitment point in T cells entering the cell cycle after stimulation.
  • To investigate the molecular requirements and consequences of this commitment point on T cell activation, proliferation, and effector function.

Main Methods:

  • Stimulation of human CD4 and CD8 T cells with CD3 and CD28 antibodies.
  • Inhibition of cyclin-dependent kinases (CDKs) using TAT-p16(INK4A) to block cell cycle progression.
  • Analysis of cell cycle entry, cellular growth, and effector molecule expression.

Related Experiment Videos

Main Results:

  • A G(0) to G(1) commitment point was identified 3-5 hours after CD3/CD28 stimulation.
  • CDK6/4-cyclin D activity is required for transition through this commitment point, preventing cell cycle entry when inhibited.
  • Cell cycle entry and growth are coupled at this point, but effector function induction can occur independently in a quiescent, activated G(0(A)) state.

Conclusions:

  • T cell cycle entry and growth are coupled at a specific G(0) to G(1) commitment point.
  • Effector functions can be initiated independently of cell cycle entry, allowing for a quiescent, activated state (G(0(A))).
  • This discovery provides a deeper understanding of T cell activation dynamics and potential therapeutic targets.